Copyright © 2004 by the Johns Hopkins Bloomberg School of Public Health
ORIGINAL CONTRIBUTIONS |
Coffee Consumption, Gender, and Parkinson’s Disease Mortality in the Cancer Prevention Study II Cohort: The Modifying Effects of Estrogen
1 Department of Nutrition, Harvard School of Public Health, Boston, MA.
2 Department of Epidemiology, Harvard School of Public Health, Boston, MA.
3 The Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA.
4 Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Caffeine consumption is associated with a reduced risk of Parkinson’s disease in men but not in women. This gender difference may be due to an interaction between caffeine and use of postmenopausal estrogens. The authors prospectively assessed the relation between coffee consumption and Parkinson’s disease mortality among participants in the Cancer Prevention Study II, a cohort of over 1 million people enrolled in 1982. Causes of deaths were ascertained through death certificates from January 1, 1989, through 1998. Parkinson’s disease was listed as a cause of death in 909 men and 340 women. After adjustment for age, smoking, and alcohol intake, coffee consumption was inversely associated with Parkinson’s disease mortality in men (ptrend = 0.01) but not in women (p = 0.6). In women, this association was dependent on postmenopausal estrogen use; the relative risk for women drinking 4 or more cups (600 ml) of coffee per day compared with nondrinkers was 0.47 (95% confidence interval: 0.27, 0.80; p = 0.006) among never users and 1.31 (95% confidence interval: 0.75, 2.30; p = 0.34) among users. These results suggest that caffeine reduces the risk of Parkinson’s disease but that this hypothetical beneficial effect may be prevented by use of estrogen replacement therapy.
coffee; estrogens; mortality; Parkinson disease
Abbreviations: Abbreviations: CI, confidence interval; RR, relative risk.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Ritchie, I. Carriere, A. de Mendonca, F. Portet, J. F. Dartigues, O. Rouaud, P. Barberger-Gateau, and M. L. Ancelin The neuroprotective effects of caffeine: A prospective population study (the Three City Study) Neurology, August 7, 2007; 69(6): 536 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Klatsky, C. Morton, N. Udaltsova, and G. D. Friedman Coffee and Cirrhosis: Active Ingredients?--Reply Arch Intern Med, November 27, 2006; 166(21): 2405 - 2405. [Full Text] [PDF]
|
|
|
|
 |
|
 B. M Popkin, L. E Armstrong, G. M Bray, B. Caballero, B. Frei, and W. C Willett A new proposed guidance system for beverage consumption in the United States Am. J. Clinical Nutrition, March 1, 2006; 83(3): 529 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A H Evans, A D Lawrence, J Potts, L MacGregor, R Katzenschlager, K Shaw, J Zijlmans, and A J Lees Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 317 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Glatt, A. D. Wahner, D. J. White, A. Ruiz-Linares, and B. Ritz Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women Hum. Mol. Genet., January 15, 2006; 15(2): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Xu, Y. Xu, D. Brown-Jermyn, J.-F. Chen, A. Ascherio, D. E. Dluzen, and M. A. Schwarzschild Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease J. Neurosci., January 11, 2006; 26(2): 535 - 541. [Abstract] [Full Text] [PDF]
|
|